Oct 6, 2026 04:30PM
Oct 5, 2026 04:00AM
Oct 5, 2026 04:00AM
Sep 16, 2026 01:24AM
Aug 24, 2026 05:16AM
Aug 14, 2026 07:14AM
Jul 29, 2026 09:26AM FDA closes inspection of Alvotech's Iceland facility with VAI rating
Jul 29, 2026 09:25AM
May 11, 2026 04:50AM
May 11, 2026 04:30AM
Mar 24, 2026 09:33AM
Dec 19, 2025 05:13AM
Dec 19, 2025 03:30AM
Dec 19, 2025 03:30AM Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
Dec 17, 2025 08:39AM
Nov 6, 2025 09:00AM
Nov 6, 2025 09:00AM
Nov 4, 2025 04:49AM
Nov 3, 2025 03:52AM
Nov 2, 2025 05:12PM
Nov 2, 2025 05:10PM Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
Oct 6, 2025 08:00AM
Sep 22, 2025 05:11AM
Sep 22, 2025 04:30AM
Sep 19, 2025 07:46AM
Sep 19, 2025 07:45AM
Aug 21, 2025 04:30AM
Jul 9, 2025 04:30AM Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
Jul 9, 2025 04:30AM
Jun 23, 2025 05:14AM
Jun 23, 2025 04:00AM
Jun 23, 2025 04:00AM
May 28, 2025 06:15AM
May 7, 2025 04:45PM
May 5, 2025 07:03AM Alvotech (ALVO) and Teva (TEVA) Announce FDA Approval of Interchangeability for SELARSDI with Stelara
May 5, 2025 07:00AM
Mar 26, 2025 06:34PM
Mar 18, 2025 08:32AM
Mar 18, 2025 08:30AM
Feb 21, 2025 06:26AM
Feb 21, 2025 06:00AM
Feb 18, 2025 06:00AM Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Feb 18, 2025 06:00AM
Jan 27, 2025 06:02AM
Jan 27, 2025 06:00AM
Jan 27, 2025 06:00AM
Nov 13, 2024 04:05PM
Oct 22, 2024 07:07AM
Oct 22, 2024 07:00AM Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara®
May 20, 2024 08:25PM

334,281 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All